IGFBP7激活急性髓系白血病干/祖细胞中的维甲酸诱导反应
该研究在急性早幼粒细胞白血病(APL)细胞中鉴定胰岛素样生长因子结合蛋白7(IGFBP7)为全反式维甲酸(ATRA)诱导反应的一部分。在RARA高表达的非APL AML样本中,重组人IGFBP7(rhIGFBP7)联合ATRA可诱导分化、细胞死亡并抑制白血病干/祖细胞存活,机制部分涉及转录因子GFI1减少。小鼠移植实验显示联合治疗显著减少原代AML植入。
要点
- ATRA联合三氧化二砷或化疗使APL治愈率>90%,但其他AML亚型5年生存率仅30%。
- rhIGFBP7联合ATRA在RARA高表达的非APL AML中增强ATRA反应。
- 联合治疗减少小鼠原代AML植入,机制部分为GFI1降低。
核心结论
- IGFBP7与ATRA联合可能用于清除原代AML(白血病干/祖)细胞并减少复发。
研究设计与样本
- 研究在APL细胞中鉴定ATRA诱导的IGFBP7,并在非APL AML样本及小鼠移植模型中测试rhIGFBP7联合ATRA。
主要发现
- ATRA联合低剂量三氧化二砷或化疗使APL治愈率>90%。
- 仅30%的AML患者诊断后存活5年。
- rhIGFBP7增加RARA高表达非APL AML样本中的ATRA驱动反应。
- rhIGFBP7联合ATRA显著减少小鼠原代AML植入。
- ATRA与rhIGFBP7协同至少部分由于转录因子GFI1减少。
临床怎么用
- 对于RARA高表达的非APL AML,可考虑IGFBP7联合ATRA以增强ATRA反应并靶向白血病干/祖细胞。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA) in combination with low doses of arsenic trioxide or chemotherapy leads to exceptionally high cure rates (>90%). ATRA forces APL cells into differentiation and cell death. Unfortunately, ATRA-based therapy has not been effective among any other acute myeloid leukemia (AML) subtype, and long-term survival rates remain unacceptably low; only 30% of AML patients survive 5 years after diagnosis. Here, we identified insulin-like growth factor binding protein 7 (IGFBP7) as part of ATRA-induced responses in APL cells. Most importantly, we observed that addition of recombinant human IGFBP7 (rhIGFBP7) increased ATRA-driven responses in a subset of non-APL AML samples: those with high RARA expression. In nonpromyelocytic AML, rhIGFBP7 treatment induced a transcriptional program that sensitized AML cells for ATRA-induced differentiation, cell death, and inhibition of leukemic stem/progenitor cell survival. Furthermore, the engraftment of primary AML in mice was significantly reduced following treatment with the combination of rhIGFBP7 and ATRA. Mechanistically, we showed that the synergism of ATRA and rhIGFBP7 is due, at least in part, to reduction of the transcription factor GFI1. Together, these results suggest a potential clinical utility of IGFBP7 and ATRA combination treatment to eliminate primary AML (leukemic stem/progenitor) cells and reduce relapse in AML patients.
引用
- van Gils N, Verhagen HJMP, Rutten A, et al. IGFBP7 activates retinoid acid-induced responses in acute myeloid leukemia stem and progenitor cells. Blood Adv. 2020. PMID: 33351133. doi:10.1182/bloodadvances.2020002812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。